Northcape Wealth Management LLC Grows Position in Becton, Dickinson and Company $BDX

Northcape Wealth Management LLC grew its position in Becton, Dickinson and Company (NYSE:BDX) by 30.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,177 shares of the medical instruments supplier’s stock after purchasing an additional 3,088 shares during the period. Northcape Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $2,466,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BDX. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC boosted its position in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the period. PFG Investments LLC grew its stake in shares of Becton, Dickinson and Company by 32.7% in the second quarter. PFG Investments LLC now owns 2,601 shares of the medical instruments supplier’s stock valued at $448,000 after buying an additional 641 shares in the last quarter. Lecap Asset Management Ltd. purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $284,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,639 shares of the medical instruments supplier’s stock worth $6,311,000 after acquiring an additional 1,792 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 2,680 shares of company stock valued at $539,848. 0.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on BDX shares. Jefferies Financial Group increased their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Bank of America raised their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $209.00.

Becton, Dickinson and Company Price Performance

BDX opened at $203.56 on Friday. The company has a market capitalization of $58.00 billion, a P/E ratio of 34.92, a PEG ratio of 2.22 and a beta of 0.23. The company has a 50-day moving average of $198.54 and a 200-day moving average of $191.32. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. During the same period last year, the firm earned $3.81 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.